Gelesis Holdings, INC. Stock: price and insider trades · United States · SEC (Form 4)

About Gelesis Holdings, INC.

Gelesis Holdings, Inc. is a U.S.-listed biotherapeutics company that has traded on the NYSE under the symbol GLS, making it part of the U.S. public market universe relevant to NYSE/NASDAQ investors. The company’s business has centered on a proprietary hydrogel technology designed to work mechanically in the gastrointestinal tract rather than through a systemic chemical mechanism. In practical terms, Gelesis has aimed to address obesity and weight management with an oral, non-systemic approach that differentiates it from many conventional prescription therapies. The company traces its roots to Gelesis, Inc., a life-sciences venture built over several years through private financing rounds and clinical development work before becoming a public company. Its headquarters are in Boston, Massachusetts, United States, placing it in one of the strongest biotech clusters in North America. Historically, the organization has been best known for Plenity, its lead product, which was designed as an oral hydrogel-based aid intended to increase feelings of fullness and support weight loss in certain overweight and obese adults. Earlier pipeline references also included programs such as Gelesis100 and Gelesis200, although investors should treat historical pipeline mentions carefully because development priorities, regulatory status, and commercialization plans can change. From a competitive standpoint, Gelesis operates in a highly competitive obesity-treatment market. It faces established pharmaceutical players, emerging GLP-1-based therapies, device-oriented solutions, and broader wellness platforms. Its main differentiator is the attempt to offer a non-systemic, orally administered alternative that may appeal to patients and clinicians looking for a different risk-benefit profile than injectable anti-obesity drugs. That said, differentiation alone does not eliminate the challenges of reimbursement, physician adoption, commercial scaling, or capital intensity. Geographically, the company’s core commercial footprint has been concentrated in the United States, though its historical communications indicated interest in regulatory and commercial opportunities abroad. Recent milestones that matter for investors include the business combination with Capstar, the corporate rename to Gelesis Holdings, Inc., the NYSE listing process, and subsequent market and compliance developments. For French-speaking investors, Gelesis should be viewed as a speculative healthcare equity with meaningful execution risk, where valuation is likely to depend on product adoption, intellectual property, financing capacity, and the company’s ability to build a sustainable commercial model in the United States and potentially beyond.